Merck Vioxx Gains 60,000 Scripts Each Week; $92 Mil. In U.S. Sales To Date
Executive Summary
Nearly half of new Vioxx (refecoxib) scripts are for newly-diagnosed osteoarthritis patients or patients switching to a prescription medication from an over-the-counter treatment, Merck Investor Relations Director Laura Jordan said during a second quarter earnings teleconference July 23.